Showing 4741-4750 of 5771 results for "".
- SightGlass Vision Unveils Topline Data From Study of Novel Eyeglasses Designed to Control Myopia in Childrenhttps://modernod.com/news/sightglass-vision-unveils-topline-data-from-study-of-novel-eyeglasses-designed-to-control-myopia-in-children/2477653/SightGlass Vision announced topline data from the company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Results from a planned 12-month interim analysis of the CYPRESS clinical study (NCT03623074) demonstrated a reduction in myopia p
- David Rostov Joins CorneaGen as Chief Financial Officerhttps://modernod.com/news/david-rostov-joins-corneagen-as-chief-financial-officer/2477648/CorneaGen announced that David Rostov has joined the company as chief financial officer. Mr. Rostov has more than 20 years of C-suite experience in scaling fast-growing technology companies, mergers and acquisitions and corpor
- Ambulatory Surgery Centers Eligible For New Relief Grant Fundshttps://modernod.com/news/ambulatory-surgery-centers-eligible-for-new-relief-grant-funds-on-april-24/2477642/The Department of Health and Human Services (HHS) announced that, commencing April 24, health care providers, including ASCs, will be eligible to receive grants from a newly available pool of COVID-19 relief funds, according to The Outpatient Ophthalmic Surgery Society (OOSS). These grants are a
- Outlook Therapeutics Makes Two Appointments to Board of Directorshttps://modernod.com/news/outlook-therapeutics-makes-two-appointments-to-board-of-directors/2477639/Outlook Therapeutics announced it has bolstered its board of directors with the appointments of Prof. Dr. Gerd Auffarth and Julian Gangolli. “We are incredibly pleased to add individuals of Dr. Auffarth’s and Mr. Gangolli’s caliber to the Outlook Therapeutics Board of Directors,” Lawrence
- Visibly Offers Free Telehealth Vision Tests During COVID-19 Pandemichttps://modernod.com/news/visibly-offers-free-telehealth-vision-tests-during-covid-19-pandemic/2477627/Visibly announced that it will globally provide optometrists, ophthalmologists, and optical service providers free access to its virtual vision test technology to ensure that patients can meet their eye health needs during this unprecedented time. “We are thrilled to offer Visibly to all d
- Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeuticshttps://modernod.com/news/q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics/2477631/Q BioMed announced that together with its technology partner, Mannin Research, they are accelerating the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections. This novel drug program is being evaluated by government pro
- Novartis Acquires Amblyotech, A Provider of Digital Therapy for Treatment of Amblyopiahttps://modernod.com/news/novartis-acquires-amblyotech-a-provider-of-digital-therapy-for-treatment-of-amblyopia/2477623/Novartis announced that it has completed the acquisition of Amblyotech, a US-based software startup, and will, in collaboration with Ubisoft and McGill University, pursue the development of the acquired digital technology for the treatment of amblyopia. It is estimated that amblyopia affec
- NovaBay Pharmaceuticals Signs Agreement to Distribute COVID-19 Antibody Rapid Point-of-Care Test to US Health Care Professionalshttps://modernod.com/news/novabay-pharmaceuticals-signs-agreement-to-distribute-covid-19-antibody-rapid-point-of-care-test-to-u-s-healthcare-professionals/2477616/NovaBay Pharmaceuticals announced an agreement with Shenzhen Microprofit Biotech to become the exclusive US distributor of a rapid, finger prick test to determine the presence of COVID-19 or a potential indication of antibody immunity to COVID-19, according to a company news release. The fluoreca
- Novartis to Conduct Study of Hydroxychloroquine for Hospitalized Patients With COVID-19 Diseasehttps://modernod.com/news/novartis-to-conduct-study-of-hydroxychloroquine-for-hospitalized-patients-with-covid-19-disease/2477617/Novartis announced Monday that it reached an agreement with the FDA to begin a phase 3 study evaluating the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. The trial, which will be conduct
- Haag-Streit Group Acquires Majority Stake in VRmagichttps://modernod.com/news/haag-streit-group-acquires-majority-stake-in-vrmagic/2477610/In an effort to expand medical training for ophthalmologists, Haag-Streit announced that it has acquired a majority stake in VRmagic. VRmagic was established in 2001 and is a pioneer for virtual and augmented reality technology in medical training. The solutions developed by VRmagic permit